Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: horsegirl48 who wrote (573)	7/22/2000 2:53:23 PM
From: allen menglin chen	Read Replies (1) \| Respond to of 746

I'm not recommending to buy at this level. But I would hold my current position since it breaks out of the 90-105 trading range. And the maximum pain price for option expiration is ~100. So even the option MMs cannot push it down. In the last 3+ weeks, CRA has signed up ~4 universities, ~2 bio/phamar companies, and Australia gov. And I believe there are more signups on the way. CRA's biz model is validated. Proteomics is the next CRA project. And cancer related vaccines might be developed -- CRA might become a drug company. fool.com Short-term, the mouse genome sequence should be done in late Aug to Dec.